Corbus Pharma’s Remarkable Surge
Corbus Pharmaceuticals’ Remarkable Surge After Early Phase 1 Data on Tumor Candidate
Shares of micro-cap biotech company Corbus Pharmaceuticals (NASDAQ:CRBP) skyrocketed over 300% on Friday following the announcement of early, yet promising, data from a small group of cancer patients who were treated with its antibody-drug conjugate CRB-701 in a Phase 1 trial. Based on the data cut in December for patients with cancers expressing the tumor-associated ...












